TargetBeta
DMPK
DM1 protein kinase · also DMK, DM1PK, MDPK, MT-PK · DMPK kinase family
2 programs in company-led studies act on DMPK, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Conditions their studies are in
- Myotonic Dystrophy, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 28, 2029SAR446268 · Sanofi · phase 2 · NCT06844214
- Oct 2030AOC 1001 · Novartis · phase 3 · NCT07008469
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.